Barbara Weber
Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About Barbara Weber
Earlier roles on record: Board Member at Revolution Medicines, Inc. (RVMD) until June 26, 2025 and Board Member at Tango Therapeutics, Inc. (TNGX) until August 3, 2026. Tango Therapeutics, Inc. reported in an 8-K filed August 6, 2026 that Barbara Weber resigned as member of Company's board of directors, effective August 3, 2026. Tango Therapeutics, Inc. reported in an 8-K filed August 6, 2026 that Barbara Weber was terminated as Executive Chair, effective August 3, 2026. Tango Therapeutics, Inc. reported in an 8-K filed January 8, 2026 that Barbara Weber retired as Chief Executive Officer, effective January 8, 2026. Equibles holds 4 filed executive changes naming Barbara Weber; each is listed under recent activity with its source filing. The proxy statement of Tango Therapeutics, Inc. reports total compensation of $2,823,992 for Barbara Weber in fiscal 2025, including a base salary of $697,950. Disclosed compensation is on record for 6 fiscal years.
“Consistent with the terms of the Employment Agreement, Dr. Weber is deemed to have resigned from all officer and board member positions, including as a member of Company's board of directors (the "Board") upon the termination of Dr. Weber's employment.”
“Dr. Barbara Weber's employment with Tango Therapeutics, Inc. (the "Company") as its Executive Chair ended on August 3, 2026 in accordance with the terms of her Amended and Restated Employment Agreement dated January 8, 2026 (the "Employment Agreement").”
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
2019-01-01–2025-06-26
-
2018-01-01–2025-06-26
-
2017-01-01–2026-08-03
-
2017-01-01–2026-08-03
Company network
Recorded roles and call appearances connecting this person to public companies.
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Tango Therapeutics, Inc. (TNGX) | Executive Chairman | $697,950 | $2,823,992 |
| 2024 | Tango Therapeutics, Inc. (TNGX) | President, Chief Executive Officer and Director | $659,996 | $6,541,200 |
| 2023 | Tango Therapeutics, Inc. (TNGX) | President, Chief Executive Officer and Director | $625,997 | $3,391,059 |
| 2022 | Tango Therapeutics, Inc. (TNGX) | President, Chief Executive Officer and Director | $575,000 | $4,681,787 |
| 2021 | Tango Therapeutics, Inc. (TNGX) | President, Chief Executive Officer and Director | $513,685 | $11,515,974 |
| 2020 | Tango Therapeutics, Inc. (TNGX) | President, Chief Executive Officer and Director | $491,617 | $958,221 |
Recent activity
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.